---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-082307"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2024-07-09T23:59:59+00:00"
generated_at: "2026-05-31T22:37:02.107760+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Q32 Bio completes SIGNAL-AD Phase 2 enrollment; topline data expected Q4 2024

## Summary
- Enrolled 121 patients in SIGNAL-AD Phase 2 trial, exceeding original target of ~100.
- Part B randomized 1:1 to bempikibart 200 mg Q2W SC or placebo for 12 weeks.
- Primary endpoint: mean % change from baseline in EASI score at week 14.
- SIGNAL-AA (alopecia areata) enrollment also completed; both topline data due Q4 2024.
- CEO cites patient demand as driver of enrollment surpassing initial target.

## SEC filing metadata
- accession: 0000950170-24-082307
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2024-07-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000095017024082307/0000950170-24-082307-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000095017024082307/qttb-20240709.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-082307
- JSON: https://secwatch.observer/filing/0000950170-24-082307.json
- Plain text: https://secwatch.observer/filing/0000950170-24-082307.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.